Search
Milrinone
go.drugbank.com/drugs/DB00235ApprovedInvestigational[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483] … metabolites, resulting in complex systemic pathologies.
Mixtures: Milrinone Lactate in DextroseCategories: Compounds used in a research, industrial, or household settingInosine
go.drugbank.com/drugs/DB04335Approved(Dorland, 28th ed) … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnon 2 March 2018 [L1738]. … Although Zinbryta (daclizumab) was available for patients as needed until 30 April 2018, Biogen and Abbvie announced a voluntary withdrawal of their product Zinbryta (daclizumab) from the global market
Products: Zinbryta PenGadobutrol
go.drugbank.com/drugs/DB06703ApprovedInvestigationalGadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. … Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume.
Categories: Compounds used in a research, industrial, or household settingProducts: Gadograf 1,0 mmol/ml Injektionslösung in Fertigspritzen, Gadovist 1,0 mmol/ml Injektionslösung in Fertigspritzen/PatronenAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … [A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib].
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalEnasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalIt is available as intramuscular or intravenous injections. … Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999].
Synonyms: Asparaginase (E. coli), E. coli AsparaginaseAluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalAluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. … Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
Mixtures: Eno, EnoNevirapine
go.drugbank.com/drugs/DB00238ApprovedInvestigationalA potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.
Mixtures: ZIMODINE N ®, LAVUZID® NCategories: Antivirals used in combination for the treatment of HIV infections, Non-Nucleoside Reverse Transcriptase InhibitorsSodium carbonate
go.drugbank.com/drugs/DB09460ApprovedWithdrawnWhen dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.
Mixtures: ENO, ENO ORANGE